Literature DB >> 1377283

Expression of the neu oncogene under the transcriptional control of the myelin basic protein gene in transgenic mice: generation of transformed glial cells.

C Hayes1, D Kelly, S Murayama, A Komiyama, K Suzuki, B Popko.   

Abstract

We have taken a transgenic approach in an effort to specifically transform oligodendrocytes, the myelinating glial cells of the central nervous system (CNS). Transgenic mice were generated with a DNA construct that contained the activated neu oncogene under the transcriptional control of the myelin basic protein (MBP) gene. The MBP/c-neu transgenic animals have experienced a low incidence of brain tumors that express molecular markers specific to oligodendrocytes, providing a mouse model to study the formation and progression of oligodendrocyte tumors. A tumor from a transgenic animal has been dispersed in culture, and transformed cells that express properties of oligodendrocytes and astrocytes have been maintained. The degree to which these cells express phenotypic characteristic of oligodendrocytes or astrocytes is influenced by culture conditions. These transformed cells should serve as a valuable resource with which to study various molecular and biochemical aspects of the myelination process, as well as the lineage interrelationship of CNS glial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1377283     DOI: 10.1002/jnr.490310123

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  10 in total

1.  Neuregulin-1 enhances survival of human astrocytic glioma cells.

Authors:  Patricia S Ritch; Steven L Carroll; Harald Sontheimer
Journal:  Glia       Date:  2005-08-15       Impact factor: 7.452

2.  Box I and II motif from myelin basic protein gene promoter binds to nuclear proteins from rodent brain.

Authors:  K S Kimbro; P A Rosenberg; R A Saavedra
Journal:  J Mol Neurosci       Date:  1994       Impact factor: 3.444

3.  The cytoplasmic domain of the large myelin-associated glycoprotein isoform is needed for proper CNS but not peripheral nervous system myelination.

Authors:  N Fujita; A Kemper; J Dupree; H Nakayasu; U Bartsch; M Schachner; N Maeda; K Suzuki; B Popko
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

4.  Two proteins bind to a novel motif in the promoter of the myelin basic protein gene from mouse.

Authors:  J Torron; C I Ljubetic; L Huang; K S Kimbro; C Dyer; R A Saavedra
Journal:  J Mol Neurosci       Date:  1997-06       Impact factor: 3.444

5.  Psychosine is as potent an inducer of cell death as C6-ceramide in cultured fibroblasts and in MOCH-1 cells.

Authors:  J Tohyama; J Matsuda; K Suzuki
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

6.  Heregulins and the ErbB-2/3/4 receptors in gliomas.

Authors:  M Westphal; L Meima; E Szonyi; J Lofgren; H Meissner; W Hamel; K Nikolics; M X Sliwkowski
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

7.  Can experimental models of rodent implantation glioma be improved? A study of pure and mixed glioma cell line tumours.

Authors:  I R Whittle; D C Macarthur; G P Malcolm; M Li; K Washington; J W Ironside
Journal:  J Neurooncol       Date:  1998-02       Impact factor: 4.130

8.  Migration of fresh human malignant astrocytoma cells into hydrated gel wafers in vitro.

Authors:  J J Bernstein; W J Goldberg; E R Laws
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 9.  The effects of interferon-gamma on the central nervous system.

Authors:  B Popko; J G Corbin; K D Baerwald; J Dupree; A M Garcia
Journal:  Mol Neurobiol       Date:  1997 Feb-Apr       Impact factor: 5.590

10.  Targeted overexpression of a golli-myelin basic protein isoform to oligodendrocytes results in aberrant oligodendrocyte maturation and myelination.

Authors:  Erin C Jacobs; Samuel D Reyes; Celia W Campagnoni; M Irene Givogri; Kathy Kampf; Vance Handley; Vilma Spreuer; Robin Fisher; Wendy Macklin; Anthony T Campagnoni
Journal:  ASN Neuro       Date:  2009-09-23       Impact factor: 4.146

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.